HARROW, INC. — Director's Dealing 2016

Dec 21, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Imprimis Pharmaceuticals, Inc. (IMMY)
CIK: 0001360214
Period of Report: 2016-12-19

Reporting Person: BOLL ANDREW R. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-19	Common Stock	P	39000	$1.79	Acquired	54000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-12-19	Purchase Warrant	$1.79	P	39000	Acquired	2019-12-23	Common Stock (39000)	Direct

Footnotes

F1: On December 19, 2016, Mr. Boll entered into a definitive agreement to acquire 39,000 Units of Imprimis Pharmaceuticals, Inc.'s (the "Company"), with each Unit consisting of one share of common stock, and a warrant to purchase one share of the Company's common stock, as part of a private placement by the Company to accredited investors.

F2: The value of the Purchase Warrant included in each Unit is $0.125.